REG - Venture Life Group - Director/PDMR Shareholding <Origin Href="QuoteRef">VLG.L</Origin>

Venture LifeAnnouncement

17/05/2016 16:20

RNS Number : 5175Y
Venture Life Group PLC
17 May 2016
Venture Life Group PLC
("Venture Life" or the "Company")
Director/PDMR Shareholding
Bracknell, UK - 17 May 2016: Venture Life Group plc (AIM: VLG), the international consumer healthcare group addressing the self-care needs of the ageing population, announces that it was informed on 17 May 2016 that Mr. Jerry Randall, the Chief Executive Officer of the Company, has transferred 31,250 ordinary shares of 0.3p each in the Company ("Ordinary Shares") to his ISA (the "Transfer"). The Transfer was made on 16 May 2016 by way of a sale at a price of 62.00p per Ordinary Share and purchase at a price of 62.10p per Ordinary Share. Following the Transfer, Mr. Randall's beneficial interest in the Company remains unchanged at 3,931,129 Ordinary Shares, representing approximately 10.7% of the issued share capital in the Company.
The Company previously announced on 9 May 2016 that Mr. Randall had sold and bought 20,000 Ordinary Shares as part of a transfer of Ordinary Shares to his SIPP. The announcement should have stated that the transfer was to his ISA, not to his SIPP.
For further information please contact:
Venture Life Group PLC
Jerry Randall, Chief Executive Officer +44 (0)1344 742 870
James Hunter, Chief Financial Officer  
Panmure Gordon (UK) Limited (Nominated Adviser and Broker)  
Freddy Crossley +44 (0) 20 7886 2500
Peter Steel
Duncan Monteith
Corporate Finance
Tom Salvesen
Corporate Broking 
Square1 Consulting
David Bick
Brian Alexander  +44 (0)20 7929 5599
About Venture Life 
Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the ageing population. The Group's product range and pipeline currently includes the UltraDEX oral care products range, food supplements for lowering cholesterol and maintaining brain function, dermo-cosmetics for addressing the signs of ageing, and medical devices for improving minor aches and pains, dry eyes and itchy skin. The products, which typically are recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners.
Through its manufacturing company, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
DSHLLFLEERIDLIR